In a recent study, researchers have uncovered the biological trigger behind the dangerous immune-related adverse events (irAEs) that occur when the ...

The authorisation comes three months after the MHRA approved Johnson & Johnson’s Lazcluze (lazertinib), which is also ...

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ('Kelun-Biotech', 6990.HK) today announced that results from its ...

In a recent study, researchers have uncovered the biological trigger behind the dangerous immune-related adverse events ...

BeOne Medicines' robust financial outlook is driven by zanubrutinib's rapid sales growth and anticipated positive cash flow.

Patients with stage II and IIIB non-small cell lung cancer (NSCLC) with an EGFR mutation had better outcomes when treated ...

The MHRA has approved aumolertinib for adult patients with non-small cell lung cancer (NSCLC), following a groundbreaking ...

Lung cancer is the malignant tumor with the highest incidence and mortality rate in the world. With the in-depth research of ...

The use of tyrosine kinase inhibitors (TKIs) in the treatment of epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) has not produced the same durable clinical benefits ...

The molecular diagnostics firm's Idylla EGFR Mutation Test is used to guide targeted therapies for patients with non-small cell lung cancer.

CHICAGO -- Neoadjuvant osimertinib (Tagrisso) with or without chemotherapy significantly increased major pathologic response ...